OverviewSuggest Edit

DiaCarta provides precise cancer molecular tests including NRAS, EGFR and KRAS mutation test kits, PCR ready lysis kit, HPV E6/E7 mRNA test kits for cervical and head-neck cancer, cancer biomarker gene expression detection kits and superfast master mix. DiaCarta supplies precise molecular diagnostic cancer assays that enable the most sensitive, reliable, and accurate detection of cancer biomarkers directly from a patient sample, including QClamp gene mutation tests, SuperbDNA gene expression assays, and QZol, the only PCR ready lysate solution . DiaCarta's NRAS, EGFR, and KRAS tests are highly sensitive and able to detect a broad set of mutations and are being used by hospitals and cancer clinical laboratories for the treatment of patients and by biotechnology and pharmaceutical companies for clinical research. ... Show more
TypePrivate
HQRichmond, US
Websitediacarta.com

Latest Updates

Employees (est.) (Feb 2019)40(+6%)

Key People/Management at DiaCarta

Aiguo Zhang

Aiguo Zhang

President & CEO
Paul Okunieff

Paul Okunieff

CMO
Show more

DiaCarta Office Locations

DiaCarta has an office in Richmond
Richmond, US (HQ)
2600 Hilltop Dr
Show all (1)
Report incorrect company information

DiaCarta Financials and Metrics

Summary Metrics

DiaCarta total Funding

$8 m

DiaCarta latest funding size

$8 m

Time since last funding

4 years ago

DiaCarta investors

DiaCarta's latest funding round in January 2015 was reported to be $8 m. In total, DiaCarta has raised $8 m
Show all financial metrics
Report incorrect company information

DiaCarta Online and Social Media Presence

Embed Graph
Report incorrect company information

DiaCarta Blogs

cfDNA Quantitation for Research and Clinical Applications

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standa…

CIO Bulletin Announces DiaCarta Inc. As One of the 30 Fastest Growing Companies of 2018

DiaCarta announced that CIO Bulletin has named it among the 30 Fastest Growing Companies of 2018. The positioning is based on DiaCarta’s revenue growth, financial status, openness to innovation, global collaboration and partnership, flagship products launching, regulatory progress and ability to for…

Confirmation of NGS for False-negative Variants Using XNA Technology

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standa…

DiaCarta Company Life and Culture

Report incorrect company information

DiaCarta Frequently Asked Questions

  • Who are DiaCarta key executives?

    DiaCarta's key executives are Aiguo Zhang and Paul Okunieff.

  • How many employees does DiaCarta have?

    DiaCarta has 40 employees.

  • Who are DiaCarta competitors?

    Competitors of DiaCarta include Exco InTouch, Inventiva and Orbit Discovery.

  • Where is DiaCarta headquarters?

    DiaCarta headquarters is located at 2600 Hilltop Dr, Richmond.

  • Where are DiaCarta offices?

    DiaCarta has an office in Richmond.

  • How many offices does DiaCarta have?

    DiaCarta has 1 office.